Embedded Files
Wikipedia 🌐 NONE
Wikipedia 🌐 NONE
ASSOCIATIONS
ASSOCIATIONS
MicroGeneSys, Incorporated ( ... )
https://www.ancestry.com/discoveryui-content/view/44879916:1788?tid=&pid=&queryId=a312ccffc36fb8a64022f394498510d1&_phsrc=llt685&_phstart=successSource
Name : Franklin Volvovitz
Birth Date : 9 Sep 1948
Residence Date : 1995
Address : 12 Indian Trail Rd / Woodbridge, CT / 06525
Second Residence Date : 1995
Second Address : PO Box 9666 / New Haven, CT / 06536-0666
Frank Volvovitz
President at Biomedisyn Corporation
Woodbridge, Connecticut, United States
https://www.linkedin.com/in/frank-volvovitz-6328b585/
2021-09-09-linkedin-com-frank-volovovitz.pdf
https://drive.google.com/file/d/1ls7RrzUQsOXgVP1xjjRiym6Qjy5i8AQD/view?usp=sharing
2021-09-09-linkedin-com-frank-volovovitz-img-1.jpg
https://drive.google.com/file/d/1dfs_HAKaD_nHatSyK9lD78_hSQ1PpZoT/view?usp=sharing
Experience
Experience
Frank founded Biomedisyn and has served as its President since inception. Biomedisyn is developing small molecule, multifunctional drugs to improve the lives of people with neurodegenerative diseases. The Company’s product pipeline has been supported by grants from the National Institutes of Health (NIH) and the United States Army.
There is growing recognition that effective treatment of neurodegenerative diseases may require drugs or drug combinations that simultaneously target multiple mechanisms. Available drugs mainly target a single mechanism and do not effectively slow disease progression. Biomedisyn’s drug candidates target multiple events in a disease pathway attenuating mechanisms common to many neurological disorders that underlie disease progression and clinical deterioration.
see less
Frank founded and served as the President and Chief Executive Officer (May 1983 until December 1994) of Protein Sciences Corp. (formerly MicroGeneSys, Inc.) a biotechnology company engaged in the development of new vaccines. In January 2013, the recombinant influenza vaccine pioneered by his team received FDA approval under the trade name of Flublok. Additionally, under Frank's leadership, new vaccines for malaria, HIV/AIDS and colon cancer were brought from concept to human clinical trials. Their development required first the creation of a new vaccine manufacturing platform based on the use of a recombinant insect virus and insect cells, which his team pioneered in connection with developing the first HIV/AIDS vaccine to enter U.S. clinical trials. He established a strategic collaboration with American Home Products (now Pfizer) that provided a multimillion equity investment and supported further development of the HIV/AIDS vaccine. He arranged multiple rounds of private financing and a multimillion dollar loan for Protein Sciences with the State of Connecticut and City of Meriden.
Page updated
Report abuse